Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Enhertu® (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody and topoisomerase inhibitor conjugate, for the treatment of adults with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-negative) breast cancer who have received a prior therapy in the metastatic setting.
The sBLA is supported by data from the open-label, phase 3 DESTINY-Breast04 trial (ClinicalTrials.gov Identifier: NCT03734029), which evaluated the safety and efficacy of Enhertu in 557 adults with unresectable or metastatic HER2-low breast cancer who had received 1 or 2 previous lines of chemotherapy.
HER2-low status was defined as an IHC score of 1+ or IHC 2+ with a negative ISH score. Patients were randomly assigned 2:1 to receive either Enhertu or physician’s choice of treatment (capecitabine, eribulin, gemcitabine, paclitaxel, nab-paclitaxel).
Results showed that among patients with hormone receptor-positive disease (n=494), median progression-free survival (PFS; primary endpoint) was 10.1 months in the Enhertu arm and 5.4 months in the physician’s choice of chemotherapy arm (hazard ratio [HR], 0.51; P <.001); overall survival (OS) was 23.9 months and 17.5 months, respectively (HR, 0.64; P =.003).
Among all patients, median PFS was 9.9 months in the Enhertu arm and 5.1 months in the physician’s choice of chemotherapy arm (HR, 0.50; P <.001), and OS was 23.4 months and 16.8 months, respectively (HR, 0.64; P =.001).
“The data from DESTINY-Breast04 represent the first time a HER2-targeted therapy has shown a survival benefit in patients with HER2-low metastatic breast cancer,” said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. “If approved, Enhertu will redefine how we classify and treat metastatic breast cancer, enabling patients whose tumors have lower levels of HER2 expression the opportunity to benefit from a HER2-directed therapy.”
The FDA previously granted Breakthrough Therapy designation to Enhertu for this indication. The safety profile of Enhertu was consistent with previous clinical trials; no new safety concerns were identified.
Enhertu is currently approved for the treatment of unresectable or metastatic HER2-positive breast cancer in patients who have received 2 or more prior anti-HER2-based regimens in the metastatic setting. It is also indicated for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimen.
References
- Enhertu® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer. News release. AstraZeneca. Accessed July 25, 2022. https://www.businesswire.com/news/home/20220725005244/en/ENHERTU%C2%AE-fam-trastuzumab-deruxtecan-nxki-granted-Priority-Review-in-the-US-for-patients-with-HER2-low-metastatic-breast-cancer
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. Published online July 7, 2022. doi: 10.1056/NEJMoa2203690
This article originally appeared on MPR
